United States Biotechnology & Medical Research

Heron Therapeutics Inc (HRTX)

Track

Track

Heron Therapeutics Inc. recorded significant insider buying activity on August 8, 2025, involving Rubric Capital Management LP and Adam Morgan. These acquisitions represent the most recent transactions for the firm. Prior to this date, various executives engaged in purchasing shares throughout late 2023, reflecting historical patterns of accumulation by key stakeholders.
Ticker: HRTX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Heron Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.9
Morgan Adam Non-Executive Director
Transaction date
Purchase
Price
80.45
Quantity 11,530 -26.8%
Value US$648,363
3.4
Forbes William P EVP, Chief Development Officer Officer
Transaction date
Purchase
Price
274.47
Quantity 37,754 +43.9%
Value US$3,797,479
3.4
Forbes William P EVP, Chief Development Officer Officer
Transaction date
Purchase
Price
0.94
Quantity 50,000 +1250.0%
Value US$46,995
3.7
Collard Craig A Chief Executive Officer Executive Director
Transaction date
Purchase
Price
0.92
Quantity 150,000 +411.0%
Value US$137,970
3.4
Duarte Ira EVP, Chief Financial Officer Officer
Transaction date
Purchase
Price
0.89
Quantity 85,000 +inf%
Value US$75,599
1.9
Morgan Adam Non-Executive Director
Transaction date
Purchase
Price
1.37
Quantity 2,486,744 +55.3%
Value US$3,406,839
3.0
MANHARD KIMBERLY EVP, Drug Development Executive Director
Transaction date
Planned sale
Price
4.76
Quantity 1,504 -12.2%
Value US$7,154
Johnson Craig A Non-Executive Director
Transaction date
Planned sale
Price
9.73
Quantity 250 -8.1%
Value US$2,432
2.5
Christian Waage Non-Executive Director
Transaction date
Planned sale
Price
9.73
Quantity 300 -8.6%
Value US$2,920
2.5
Christian Waage Non-Executive Director
Transaction date
Planned sale
Price
15.20
Quantity 300 -7.3%
Value US$4,559
Johnson Craig A Non-Executive Director
Transaction date
Planned sale
Price
15.20
Quantity 250 -7.0%
Value US$3,801
2.5
Christian Waage Non-Executive Director
Transaction date
Planned sale
Price
17.51
Quantity 300 -6.8%
Value US$5,254
Johnson Craig A Non-Executive Director
Transaction date
Planned sale
Price
17.22
Quantity 250 -6.5%
Value US$4,305
Szekeres David Leslie EVP, Chief Operating Officer Officer
Transaction date
Planned sale
Price
18.09
Quantity 827 -100.0%
Value US$14,960
Szekeres David Leslie EVP, Chief Operating Officer Officer
Transaction date
Planned sale
Price
19.66
Quantity 3,571 -100.0%
Value US$70,219
3.0
MANHARD KIMBERLY EVP, Drug Development Executive Director
Transaction date
Planned sale
Price
20.00
Quantity 10,000 -100.0%
Value US$200,000
3.0
MANHARD KIMBERLY Executive VP, Drug Development Executive Director
Transaction date
Planned sale
Price
13.97
Quantity 1,158 -100.0%
Value US$16,176
MANHARD KIMBERLY Executive VP, Drug Development Executive Director
Transaction date
Planned sale
Price
26.00
Quantity 24,000 -100.0%
Value US$624,000
3.3
TANG KEVIN C
Transaction date
Purchase
Price
17.50
Quantity 285,714 +5.2%
Value US$4,999,995
2.5
Quart Barry D Chief Executive Officer Executive Director
Transaction date
Purchase
Price
17.50
Quantity 4,571 +5.1%
Value US$79,992
2.8
POYHONEN JOHN EVP, Chief Commercial Officer Executive Director
Transaction date
Purchase
Price
17.50
Quantity 5,143 +39.6%
Value US$90,002
2.8
POYHONEN JOHN Non-Executive Director
Transaction date
Purchase
Price
17.55
Quantity 3,000 +30.0%
Value US$52,650
2.5
Christian Waage
Transaction date
Purchase
Price
18.04
Quantity 1,400 +inf%
Value US$25,262
3.0
MANHARD KIMBERLY Executive VP, Drug Development Officer
Transaction date
Planned sale
Price
18.86
Quantity 1,109 -100.0%
Value US$20,918
MANHARD KIMBERLY Executive VP, Drug Development Officer
Transaction date
Planned sale
Price
30.62
Quantity 494 -100.0%
Value US$15,125
MANHARD KIMBERLY Executive VP, Drug Development Officer
Transaction date
Planned sale
Price
32.07
Quantity 6,000 -100.0%
Value US$192,433
TANG KEVIN C Non-Executive Director Large shareholder
Transaction date
Sale
Price
35.75
Quantity 2,695,000 -31.6%
Value US$96,346,250
Rosen Robert President Executive Director
Transaction date
Planned sale
Price
38.75
Quantity 3,400 -56.3%
Value US$131,765
Rosen Robert President Executive Director
Transaction date
Planned sale
Price
38.13
Quantity 92,131 -93.8%
Value US$3,512,918
MANHARD KIMBERLY Executive VP, Drug Development Officer
Transaction date
Planned sale
Price
38.85
Quantity 100 -100.0%
Value US$3,885
MANHARD KIMBERLY Executive VP, Drug Development Officer
Transaction date
Planned sale
Price
37.51
Quantity 5,900 -98.3%
Value US$221,294
HOFFMAN ROBERT CFO & SVP, Finance Officer
Transaction date
Planned sale
Price
38.80
Quantity 1,060 -45.3%
Value US$41,123
HOFFMAN ROBERT CFO & SVP, Finance Officer
Transaction date
Planned sale
Price
38.15
Quantity 28,940 -92.5%
Value US$1,104,107
Rosen Robert President Executive Director
Transaction date
Planned sale
Price
41.39
Quantity 2,112 -44.4%
Value US$87,415
Rosen Robert President Executive Director
Transaction date
Planned sale
Price
40.17
Quantity 51,696 -91.6%
Value US$2,076,597
Rosen Robert President Executive Director
Transaction date
Planned sale
Price
39.14
Quantity 75,661 -57.3%
Value US$2,961,122
Quart Barry D Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
39.05
Quantity 50,000 -41.8%
Value US$1,952,500
TANG KEVIN C Large shareholder
Transaction date
Purchase
Price
26.00
Quantity 192,308 +2.3%
Value US$5,000,008
MANHARD KIMBERLY Executive VP, Drug Development
Transaction date
Planned sale
Price
30.00
Quantity 18,000 -100.0%
Value US$540,000
Quart Barry D Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
29.75
Quantity 100,000 -59.5%
Value US$2,975,000
Quart Barry D Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
24.75
Quantity 100,000 -59.5%
Value US$2,475,000
MANHARD KIMBERLY Executive VP, Drug Development Officer
Transaction date
Planned sale
Price
20.00
Quantity 7,584 -100.0%
Value US$151,680
MANHARD KIMBERLY Executive VP, Drug Development
Transaction date
Planned sale
Price
15.33
Quantity 21,542 -100.0%
Value US$330,263
POYHONEN JOHN
Transaction date
Purchase
Price
12.20
Quantity 10,000 +inf%
Value US$122,000
TANG KEVIN C Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.20
Quantity 2,459,016 +41.9%
Value US$29,999,995
Rosen Robert President & CCO Executive Director
Transaction date
Planned sale
Price
23.89
Quantity 12,400 -82.4%
Value US$296,278
Rosen Robert President & CCO Executive Director
Transaction date
Planned sale
Price
23.21
Quantity 87,600 -85.3%
Value US$2,033,616
Rosen Robert President Executive Director
Transaction date
Planned sale
Price
22.15
Quantity 19,662 -88.2%
Value US$435,433
Rosen Robert President Executive Director
Transaction date
Planned sale
Price
22.19
Quantity 4,010 -60.3%
Value US$88,967
Rosen Robert President Executive Director
Transaction date
Planned sale
Price
25.11
Quantity 6,230 -70.2%
Value US$156,438
Rosen Robert President Executive Director
Transaction date
Planned sale
Price
24.49
Quantity 32,224 -78.4%
Value US$789,037
Rosen Robert President Executive Director
Transaction date
Planned sale
Price
23.47
Quantity 76,949 -65.2%
Value US$1,805,955
Rosen Robert President Executive Director
Transaction date
Planned sale
Price
22.50
Quantity 60,925 -34.0%
Value US$1,370,593
TANG KEVIN C Non-Executive Director Large shareholder
Transaction date
Purchase
Price
24.75
Quantity 121,212 +2.6%
Value US$2,999,997
MANHARD KIMBERLY Non-Executive Director
Transaction date
Sale
Price
23.58
Quantity 10,500 -100.0%
Value US$247,590
TANG KEVIN C Non-Executive Director Large shareholder
Transaction date
Purchase
Price
23.84
Quantity 32,395 +0.7%
Value US$772,294
MANHARD KIMBERLY Non-Executive Director
Transaction date
Sale
Price
21.17
Quantity 2,708 -100.0%
Value US$57,328
TANG KEVIN C Non-Executive Director Large shareholder
Transaction date
Purchase
Price
19.30
Quantity 2,380 +0.1%
Value US$45,934
TANG KEVIN C Non-Executive Director Large shareholder
Transaction date
Purchase
Price
19.74
Quantity 115,225 +2.5%
Value US$2,274,058
Marshall Paul SVP, Technical Operations Officer
Transaction date
Planned sale
Price
15.40
Quantity 20,000 -100.0%
Value US$308,000
Marshall Paul SVP, Technical Operations Officer
Transaction date
Planned sale
Price
14.40
Quantity 50,000 -71.4%
Value US$720,000
TANG KEVIN C Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.75
Quantity 510,638 +12.5%
Value US$5,999,996
Quart Barry D Chief Executive Officer Executive Director
Transaction date
Purchase
Price
11.75
Quantity 10,000 +19.3%
Value US$117,500
Quart Barry D Chief Executive Officer Executive Director
Transaction date
Purchase
Price
0.40
Quantity 1,000,000 +2695.4%
Value US$400,000
SPCH, LLLP Large shareholder
Transaction date
Purchase
Price
0.53
Quantity 38,095,238 +inf%
Value US$20,000,000
TANG KEVIN C Non-Executive Director Large shareholder
Transaction date
Purchase
Price
0.88
Quantity 2,443,181 +30.6%
Value US$2,149,999
TANG KEVIN C Large shareholder
Transaction date
Purchase
Price
0.42
Quantity 175,000 +2.2%
Value US$72,625
TANG KEVIN C Large shareholder
Transaction date
Purchase
Price
0.48
Quantity 415,300 +5.6%
Value US$200,673
TANG KEVIN C Large shareholder
Transaction date
Purchase
Price
0.48
Quantity 775,032 +11.7%
Value US$372,015
TANG KEVIN C Large shareholder
Transaction date
Purchase
Price
0.50
Quantity 66,000 +1.0%
Value US$32,710
ROSENBLATT TOBY Non-Executive Director
Transaction date
Sale
Price
0.51
Quantity 40,000 -100.0%
Value US$20,524
ROSENBLATT TOBY Non-Executive Director
Transaction date
Sale
Price
0.51
Quantity 6,881 -18.5%
Value US$3,531
TANG KEVIN C Large shareholder
Transaction date
Purchase
Price
0.61
Quantity 336,300 +5.4%
Value US$204,067
TANG KEVIN C Large shareholder
Transaction date
Purchase
Price
0.74
Quantity 870,000 +16.2%
Value US$647,019
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-08-12 2025-08-08 B Purchase
3.6
Rubric Capital Management LP
Large shareholder
40,479 +23.7%
27.99
US$1,359,174 		40,479 +23.7% 27.99 US$1,359,174
2025-08-12 2025-08-08 B Purchase
1.9
Morgan Adam
Non-Executive Director
11,530 -26.8%
80.45
US$648,363 		11,530 -26.8% 80.45 US$648,363
2023-11-21 2023-11-17 B Purchase
3.4
Forbes William P

EVP, Chief Development Officer

Officer
37,754 +43.9%
274.47
US$3,797,479 		37,754 +43.9% 274.47 US$3,797,479
2023-11-20 2023-11-16 B Purchase
3.4
Forbes William P

EVP, Chief Development Officer

Officer
50,000 +1250.0%
0.94
US$46,995 		50,000 +1250.0% 0.94 US$46,995
2023-11-17 2023-11-16 B Purchase
3.7
Collard Craig A

Chief Executive Officer

Executive Director
150,000 +411.0%
0.92
US$137,970 		150,000 +411.0% 0.92 US$137,970
2023-11-17 2023-11-16 B Purchase
3.4
Duarte Ira

EVP, Chief Financial Officer

Officer
85,000 +inf%
0.89
US$75,599 		85,000 +inf% 0.89 US$75,599
2023-07-25 2023-07-21 B Purchase
1.9
Morgan Adam
Non-Executive Director
2,486,744 +55.3%
1.37
US$3,406,839 		2,486,744 +55.3% 1.37 US$3,406,839
2022-05-04 2022-05-03 PlS Planned sale
3.0
MANHARD KIMBERLY

EVP, Drug Development

Executive Director
1,504 -12.2%
4.76
US$7,154 		1,504 -12.2% 4.76 US$7,154
2021-12-23 2021-12-21 PlS Planned sale
Johnson Craig A
Non-Executive Director
250 -8.1%
9.73
US$2,432 		250 -8.1% 9.73 US$2,432
2021-12-23 2021-12-21 PlS Planned sale
2.5
Christian Waage
Non-Executive Director
300 -8.6%
9.73
US$2,920 		300 -8.6% 9.73 US$2,920
2021-06-22 2021-06-21 PlS Planned sale
2.5
Christian Waage
Non-Executive Director
300 -7.3%
15.20
US$4,559 		300 -7.3% 15.20 US$4,559
2021-06-22 2021-06-21 PlS Planned sale
Johnson Craig A
Non-Executive Director
250 -7.0%
15.20
US$3,801 		250 -7.0% 15.20 US$3,801
2021-04-16 2021-04-15 PlS Planned sale
2.5
Christian Waage
Non-Executive Director
300 -6.8%
17.51
US$5,254 		300 -6.8% 17.51 US$5,254
2021-04-07 2021-04-06 PlS Planned sale
Johnson Craig A
Non-Executive Director
250 -6.5%
17.22
US$4,305 		250 -6.5% 17.22 US$4,305
2021-01-15 2021-01-14 PlS Planned sale
Szekeres David Leslie

EVP, Chief Operating Officer

Officer
827 -100.0%
18.09
US$14,960 		827 -100.0% 18.09 US$14,960
2021-01-08 2021-01-08 PlS Planned sale
Szekeres David Leslie

EVP, Chief Operating Officer

Officer
3,571 -100.0%
19.66
US$70,219 		3,571 -100.0% 19.66 US$70,219
2020-12-23 2020-12-22 PlS Planned sale
3.0
MANHARD KIMBERLY

EVP, Drug Development

Executive Director
10,000 -100.0%
20.00
US$200,000 		10,000 -100.0% 20.00 US$200,000
2020-05-01 2020-05-01 PlS Planned sale
3.0
MANHARD KIMBERLY

Executive VP, Drug Development

Executive Director
1,158 -100.0%
13.97
US$16,176 		1,158 -100.0% 13.97 US$16,176
2019-12-03 2019-11-29 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Executive Director
24,000 -100.0%
26.00
US$624,000 		24,000 -100.0% 26.00 US$624,000
2019-10-07 2019-10-04 B Purchase
3.3
TANG KEVIN C
285,714 +5.2%
17.50
US$4,999,995 		285,714 +5.2% 17.50 US$4,999,995
2019-10-04 2019-10-03 B Purchase
2.5
Quart Barry D

Chief Executive Officer

Executive Director
4,571 +5.1%
17.50
US$79,992 		4,571 +5.1% 17.50 US$79,992
2019-10-04 2019-10-03 B Purchase
2.8
POYHONEN JOHN

EVP, Chief Commercial Officer

Executive Director
5,143 +39.6%
17.50
US$90,002 		5,143 +39.6% 17.50 US$90,002
2019-05-23 2019-05-22 B Purchase
2.8
POYHONEN JOHN
Non-Executive Director
3,000 +30.0%
17.55
US$52,650 		3,000 +30.0% 17.55 US$52,650
2019-05-16 2019-05-15 B Purchase
2.5
Christian Waage
1,400 +inf%
18.04
US$25,262 		1,400 +inf% 18.04 US$25,262
2019-05-02 2019-05-01 PlS Planned sale
3.0
MANHARD KIMBERLY

Executive VP, Drug Development

Officer
1,109 -100.0%
18.86
US$20,918 		1,109 -100.0% 18.86 US$20,918
2018-11-02 2018-11-02 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
494 -100.0%
30.62
US$15,125 		494 -100.0% 30.62 US$15,125
2018-10-02 2018-10-01 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
6,000 -100.0%
32.07
US$192,433 		6,000 -100.0% 32.07 US$192,433
2018-09-12 2018-09-12 S Sale TANG KEVIN C Non-Executive Director Large shareholder
2,695,000 -31.6%
35.75
US$96,346,250 		2,695,000 -31.6% 35.75 US$96,346,250
2018-07-03 2018-07-02 PlS Planned sale Rosen Robert

President

Executive Director
3,400 -56.3%
38.75
US$131,765 		3,400 -56.3% 38.75 US$131,765
2018-07-03 2018-07-02 PlS Planned sale Rosen Robert

President

Executive Director
92,131 -93.8%
38.13
US$3,512,918 		92,131 -93.8% 38.13 US$3,512,918
2018-07-03 2018-07-02 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
100 -100.0%
38.85
US$3,885 		100 -100.0% 38.85 US$3,885
2018-07-03 2018-07-02 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
5,900 -98.3%
37.51
US$221,294 		5,900 -98.3% 37.51 US$221,294
2018-07-03 2018-07-02 PlS Planned sale HOFFMAN ROBERT

CFO & SVP, Finance

Officer
1,060 -45.3%
38.80
US$41,123 		1,060 -45.3% 38.80 US$41,123
2018-07-03 2018-07-02 PlS Planned sale HOFFMAN ROBERT

CFO & SVP, Finance

Officer
28,940 -92.5%
38.15
US$1,104,107 		28,940 -92.5% 38.15 US$1,104,107
2018-07-03 2018-06-29 PlS Planned sale Rosen Robert

President

Executive Director
2,112 -44.4%
41.39
US$87,415 		2,112 -44.4% 41.39 US$87,415
2018-07-03 2018-06-29 PlS Planned sale Rosen Robert

President

Executive Director
51,696 -91.6%
40.17
US$2,076,597 		51,696 -91.6% 40.17 US$2,076,597
2018-07-03 2018-06-29 PlS Planned sale Rosen Robert

President

Executive Director
75,661 -57.3%
39.14
US$2,961,122 		75,661 -57.3% 39.14 US$2,961,122
2018-06-22 2018-06-21 PlS Planned sale Quart Barry D

Chief Executive Officer

Executive Director
50,000 -41.8%
39.05
US$1,952,500 		50,000 -41.8% 39.05 US$1,952,500
2018-04-02 2018-03-29 B Purchase TANG KEVIN C Large shareholder
192,308 +2.3%
26.00
US$5,000,008 		192,308 +2.3% 26.00 US$5,000,008
2018-03-19 2018-03-19 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development
18,000 -100.0%
30.00
US$540,000 		18,000 -100.0% 30.00 US$540,000
2018-03-19 2018-03-19 PlS Planned sale Quart Barry D

Chief Executive Officer

Executive Director
100,000 -59.5%
29.75
US$2,975,000 		100,000 -59.5% 29.75 US$2,975,000
2018-03-16 2018-03-14 PlS Planned sale Quart Barry D

Chief Executive Officer

Executive Director
100,000 -59.5%
24.75
US$2,475,000 		100,000 -59.5% 24.75 US$2,475,000
2018-01-12 2018-01-10 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
7,584 -100.0%
20.00
US$151,680 		7,584 -100.0% 20.00 US$151,680
2017-04-24 2017-04-24 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development
21,542 -100.0%
15.33
US$330,263 		21,542 -100.0% 15.33 US$330,263
2017-01-23 2017-01-19 B Purchase POYHONEN JOHN
10,000 +inf%
12.20
US$122,000 		10,000 +inf% 12.20 US$122,000
2017-01-23 2017-01-19 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
2,459,016 +41.9%
12.20
US$29,999,995 		2,459,016 +41.9% 12.20 US$29,999,995
2016-08-12 2016-08-10 PlS Planned sale Rosen Robert

President & CCO

Executive Director
12,400 -82.4%
23.89
US$296,278 		12,400 -82.4% 23.89 US$296,278
2016-08-12 2016-08-10 PlS Planned sale Rosen Robert

President & CCO

Executive Director
87,600 -85.3%
23.21
US$2,033,616 		87,600 -85.3% 23.21 US$2,033,616
2016-04-21 2016-04-21 PlS Planned sale Rosen Robert

President

Executive Director
19,662 -88.2%
22.15
US$435,433 		19,662 -88.2% 22.15 US$435,433
2016-04-21 2016-04-20 PlS Planned sale Rosen Robert

President

Executive Director
4,010 -60.3%
22.19
US$88,967 		4,010 -60.3% 22.19 US$88,967
2016-04-21 2016-04-19 PlS Planned sale Rosen Robert

President

Executive Director
6,230 -70.2%
25.11
US$156,438 		6,230 -70.2% 25.11 US$156,438
2016-04-21 2016-04-19 PlS Planned sale Rosen Robert

President

Executive Director
32,224 -78.4%
24.49
US$789,037 		32,224 -78.4% 24.49 US$789,037
2016-04-21 2016-04-19 PlS Planned sale Rosen Robert

President

Executive Director
76,949 -65.2%
23.47
US$1,805,955 		76,949 -65.2% 23.47 US$1,805,955
2016-04-21 2016-04-19 PlS Planned sale Rosen Robert

President

Executive Director
60,925 -34.0%
22.50
US$1,370,593 		60,925 -34.0% 22.50 US$1,370,593
2015-06-12 2015-06-10 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
121,212 +2.6%
24.75
US$2,999,997 		121,212 +2.6% 24.75 US$2,999,997
2015-06-03 2015-06-02 S Sale MANHARD KIMBERLY Non-Executive Director
10,500 -100.0%
23.58
US$247,590 		10,500 -100.0% 23.58 US$247,590
2015-06-02 2015-06-02 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
32,395 +0.7%
23.84
US$772,294 		32,395 +0.7% 23.84 US$772,294
2015-06-03 2015-06-01 S Sale MANHARD KIMBERLY Non-Executive Director
2,708 -100.0%
21.17
US$57,328 		2,708 -100.0% 21.17 US$57,328
2015-06-02 2015-06-01 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
2,380 +0.1%
19.30
US$45,934 		2,380 +0.1% 19.30 US$45,934
2015-06-02 2015-05-29 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
115,225 +2.5%
19.74
US$2,274,058 		115,225 +2.5% 19.74 US$2,274,058
2015-03-09 2015-03-05 PlS Planned sale Marshall Paul

SVP, Technical Operations

Officer
20,000 -100.0%
15.40
US$308,000 		20,000 -100.0% 15.40 US$308,000
2015-03-09 2015-03-05 PlS Planned sale Marshall Paul

SVP, Technical Operations

Officer
50,000 -71.4%
14.40
US$720,000 		50,000 -71.4% 14.40 US$720,000
2014-06-27 2014-06-25 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
510,638 +12.5%
11.75
US$5,999,996 		510,638 +12.5% 11.75 US$5,999,996
2014-06-26 2014-06-25 B Purchase Quart Barry D

Chief Executive Officer

Executive Director
10,000 +19.3%
11.75
US$117,500 		10,000 +19.3% 11.75 US$117,500
2013-11-21 2013-11-20 B Purchase Quart Barry D

Chief Executive Officer

Executive Director
1,000,000 +2695.4%
0.40
US$400,000 		1,000,000 +2695.4% 0.40 US$400,000
2012-09-12 2012-07-25 B Purchase SPCH, LLLP Large shareholder
38,095,238 +inf%
0.53
US$20,000,000 		38,095,238 +inf% 0.53 US$20,000,000
2009-10-21 2009-10-19 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
2,443,181 +30.6%
0.88
US$2,149,999 		2,443,181 +30.6% 0.88 US$2,149,999
2009-01-05 2008-12-31 B Purchase TANG KEVIN C Large shareholder
175,000 +2.2%
0.42
US$72,625 		175,000 +2.2% 0.42 US$72,625
2008-12-22 2008-12-18 B Purchase TANG KEVIN C Large shareholder
415,300 +5.6%
0.48
US$200,673 		415,300 +5.6% 0.48 US$200,673
2008-11-17 2008-11-13 B Purchase TANG KEVIN C Large shareholder
775,032 +11.7%
0.48
US$372,015 		775,032 +11.7% 0.48 US$372,015
2008-11-17 2008-11-13 B Purchase TANG KEVIN C Large shareholder
66,000 +1.0%
0.50
US$32,710 		66,000 +1.0% 0.50 US$32,710
2008-11-12 2008-11-10 S Sale ROSENBLATT TOBY Non-Executive Director
40,000 -100.0%
0.51
US$20,524 		40,000 -100.0% 0.51 US$20,524
2008-11-12 2008-11-10 S Sale ROSENBLATT TOBY Non-Executive Director
6,881 -18.5%
0.51
US$3,531 		6,881 -18.5% 0.51 US$3,531
2008-11-04 2008-10-31 B Purchase TANG KEVIN C Large shareholder
336,300 +5.4%
0.61
US$204,067 		336,300 +5.4% 0.61 US$204,067
2008-10-14 2008-10-10 B Purchase TANG KEVIN C Large shareholder
870,000 +16.2%
0.74
US$647,019 		870,000 +16.2% 0.74 US$647,019
Explore more

More insider trading research around Heron Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America